Extracorporeal Life Support

2

Review clinical trials related to Extracorporeal Life Support. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

CytOSorb TreatMent Of Critically Ill PatientS Registry

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Participants needed: 3,000
Trial details
Biological sex: AllType: ObservationalSponsor: CytoSorbents, IncUpdated: Sep 11, 2025Locations: 28Duration: 3 Months
Eligibility criteria

Planned OR actual CytoSorb® 300 mL device utilization [+1]

Use of the CytoSorb® 300 mL device for antithrombotic removal only [+2]

Status: Recruiting

Post-Surgery Extracorporeal Life Support

Extracorporeal Life Support (ECLS) may provide pulmonary and circulatory support for patients with acute heart failure refractory to conventional medical therapy. However, indications and effectiveness of ECLS engagement post-surgery remains a concern. The investigators sought to analyze indications, modality and outcomes of PS-ECLS, to identify predictors of early and midterm survival after PS-ECLS. The investigators have recorded prospectively, and analysed data of 209 consecutive PS-ECLS patients between January 2004 and December 2018. Demographic and clinical data before, during and after PS-ECLS were collected and their influence on hospital mortality and outcomes (early and midterm) will analyse. Multivariate analysis of pre PS-ECLS implantation factors (as age, female sex , insulin-dependent diabetes, pulmonary hypertension, STS, type of surgical procedure data, pre-ECLS blood lactate level) will be made for identify prognostic risk factors of in-hospital mortality. Overall survival will be analysed, at 6 months,1-year and 5-years, respectively and the factors influencing mild/term outcome will be investigated.

Participants needed: 500
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: University of FlorenceUpdated: Apr 28, 2021Locations: 1Duration: 20 Years
Eligibility criteria

Patients underwent cardiac surgery

Age < 18 years